$BNR News

Brenntag Q4 Earnings Call Highlights

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

Burning Rock Biotech Q4 EPS $(0.20) Up From $(1.10) YoY, Sales $18.063M Up From $17.265M YoY

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Biotech Chairman And CEO Yusheng Han Acquires US$811,721 In Company ADSs Through Open Market Transactions

Burning Rock Biotech Chairman And CEO Yusheng Han Acquires US$811,721 In Company ADSs Through Open Market Transactions

Burning Rock Announces Results of 2025 Annual General Meeting

Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Reports Third Quarter 2025 Financial Results

Burning Rock Biotech Q3 EPS $(0.20) Up From $(0.50) YoY, Sales $18.488M Up From $18.331M YoY

Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer

Burning Rock Secures Japan Approval For OncoScreen Plus CDx System Detecting PIK3CA AKT1 PTEN Alterations To Guide Capivasertib Treatment

Burning Rock Biotech shares are trading higher after the company reported a year-over-year increase in Q2 financial results.

Burning Rock Reports Second Quarter 2025 Financial Results

Burning Rock Biotech Q2 EPS $(0.10) Up From $(1.40) YoY, Sales $20.737M Up From $18.650M YoY

Burning Rock Reports First Quarter 2025 Financial Results

Burning Rock Biotech Q1 EPS $(0.20) Up From $(1.60) YoY, Sales $18.34M Up From $17.40M YoY

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

Burning Rock Biotech shares are trading lower. The company reported Q4 financial results.